Global Long Acting Beta Agonist Market Growth (Status and Outlook) 2025-2031

September 2025 | 97 pages | ID: G77D8515C2E5EN
LP Information

Abstracts

According to this study, the global Long Acting Beta Agonist market size will reach US$ million by 2031.

Long-acting beta-agonists or long-acting beta adrenergic receptor agonists are class of drugs used in the management of asthma by relaxing the muscles surrounding the bronchial tubes and facilitating the opening the airways wider. Long-acting beta-agonists have a longer duration of action of at least 12 hours.

United States market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Long Acting Beta Agonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Long Acting Beta Agonist players cover Sumitomo Dainippon Pharma, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim International, Mylan, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Long Acting Beta Agonist Industry Forecast” looks at past sales and reviews total world Long Acting Beta Agonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Long Acting Beta Agonist sales for 2025 through 2031. With Long Acting Beta Agonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Long Acting Beta Agonist industry.

This Insight Report provides a comprehensive analysis of the global Long Acting Beta Agonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Long Acting Beta Agonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Long Acting Beta Agonist market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long Acting Beta Agonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long Acting Beta Agonist.

This report presents a comprehensive overview, market shares, and growth opportunities of Long Acting Beta Agonist market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Liquid
• Tablet

Segmentation by Application:

• Hospitals
• Clinics
• Ambulatory Surgical Center
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Sumitomo Dainippon Pharma
• AstraZeneca
• GlaxoSmithKline
• Boehringer Ingelheim International
• Mylan
• Teva
• Merck

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Long Acting Beta Agonist Market Size (2020-2031)
  2.1.2 Long Acting Beta Agonist Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Long Acting Beta Agonist by Country/Region (2020, 2024 & 2031)
2.2 Long Acting Beta Agonist Segment by Type
  2.2.1 Liquid
  2.2.2 Tablet
2.3 Long Acting Beta Agonist Market Size by Type
  2.3.1 Long Acting Beta Agonist Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
2.4 Long Acting Beta Agonist Segment by Application
  2.4.1 Hospitals
  2.4.2 Clinics
  2.4.3 Ambulatory Surgical Center
  2.4.4 Others
2.5 Long Acting Beta Agonist Market Size by Application
  2.5.1 Long Acting Beta Agonist Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)

3 LONG ACTING BETA AGONIST MARKET SIZE BY PLAYER

3.1 Long Acting Beta Agonist Market Size Market Share by Player
  3.1.1 Global Long Acting Beta Agonist Revenue by Player (2020-2025)
  3.1.2 Global Long Acting Beta Agonist Revenue Market Share by Player (2020-2025)
3.2 Global Long Acting Beta Agonist Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 LONG ACTING BETA AGONIST BY REGION

4.1 Long Acting Beta Agonist Market Size by Region (2020-2025)
4.2 Global Long Acting Beta Agonist Annual Revenue by Country/Region (2020-2025)
4.3 Americas Long Acting Beta Agonist Market Size Growth (2020-2025)
4.4 APAC Long Acting Beta Agonist Market Size Growth (2020-2025)
4.5 Europe Long Acting Beta Agonist Market Size Growth (2020-2025)
4.6 Middle East & Africa Long Acting Beta Agonist Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Long Acting Beta Agonist Market Size by Country (2020-2025)
5.2 Americas Long Acting Beta Agonist Market Size by Type (2020-2025)
5.3 Americas Long Acting Beta Agonist Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Long Acting Beta Agonist Market Size by Region (2020-2025)
6.2 APAC Long Acting Beta Agonist Market Size by Type (2020-2025)
6.3 APAC Long Acting Beta Agonist Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Long Acting Beta Agonist Market Size by Country (2020-2025)
7.2 Europe Long Acting Beta Agonist Market Size by Type (2020-2025)
7.3 Europe Long Acting Beta Agonist Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Long Acting Beta Agonist by Region (2020-2025)
8.2 Middle East & Africa Long Acting Beta Agonist Market Size by Type (2020-2025)
8.3 Middle East & Africa Long Acting Beta Agonist Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL LONG ACTING BETA AGONIST MARKET FORECAST

10.1 Global Long Acting Beta Agonist Forecast by Region (2026-2031)
  10.1.1 Global Long Acting Beta Agonist Forecast by Region (2026-2031)
  10.1.2 Americas Long Acting Beta Agonist Forecast
  10.1.3 APAC Long Acting Beta Agonist Forecast
  10.1.4 Europe Long Acting Beta Agonist Forecast
  10.1.5 Middle East & Africa Long Acting Beta Agonist Forecast
10.2 Americas Long Acting Beta Agonist Forecast by Country (2026-2031)
  10.2.1 United States Market Long Acting Beta Agonist Forecast
  10.2.2 Canada Market Long Acting Beta Agonist Forecast
  10.2.3 Mexico Market Long Acting Beta Agonist Forecast
  10.2.4 Brazil Market Long Acting Beta Agonist Forecast
10.3 APAC Long Acting Beta Agonist Forecast by Region (2026-2031)
  10.3.1 China Long Acting Beta Agonist Market Forecast
  10.3.2 Japan Market Long Acting Beta Agonist Forecast
  10.3.3 Korea Market Long Acting Beta Agonist Forecast
  10.3.4 Southeast Asia Market Long Acting Beta Agonist Forecast
  10.3.5 India Market Long Acting Beta Agonist Forecast
  10.3.6 Australia Market Long Acting Beta Agonist Forecast
10.4 Europe Long Acting Beta Agonist Forecast by Country (2026-2031)
  10.4.1 Germany Market Long Acting Beta Agonist Forecast
  10.4.2 France Market Long Acting Beta Agonist Forecast
  10.4.3 UK Market Long Acting Beta Agonist Forecast
  10.4.4 Italy Market Long Acting Beta Agonist Forecast
  10.4.5 Russia Market Long Acting Beta Agonist Forecast
10.5 Middle East & Africa Long Acting Beta Agonist Forecast by Region (2026-2031)
  10.5.1 Egypt Market Long Acting Beta Agonist Forecast
  10.5.2 South Africa Market Long Acting Beta Agonist Forecast
  10.5.3 Israel Market Long Acting Beta Agonist Forecast
  10.5.4 Turkey Market Long Acting Beta Agonist Forecast
10.6 Global Long Acting Beta Agonist Forecast by Type (2026-2031)
10.7 Global Long Acting Beta Agonist Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Long Acting Beta Agonist Forecast

11 KEY PLAYERS ANALYSIS

11.1 Sumitomo Dainippon Pharma
  11.1.1 Sumitomo Dainippon Pharma Company Information
  11.1.2 Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Offered
  11.1.3 Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Sumitomo Dainippon Pharma Main Business Overview
  11.1.5 Sumitomo Dainippon Pharma Latest Developments
11.2 AstraZeneca
  11.2.1 AstraZeneca Company Information
  11.2.2 AstraZeneca Long Acting Beta Agonist Product Offered
  11.2.3 AstraZeneca Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 AstraZeneca Main Business Overview
  11.2.5 AstraZeneca Latest Developments
11.3 GlaxoSmithKline
  11.3.1 GlaxoSmithKline Company Information
  11.3.2 GlaxoSmithKline Long Acting Beta Agonist Product Offered
  11.3.3 GlaxoSmithKline Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 GlaxoSmithKline Main Business Overview
  11.3.5 GlaxoSmithKline Latest Developments
11.4 Boehringer Ingelheim International
  11.4.1 Boehringer Ingelheim International Company Information
  11.4.2 Boehringer Ingelheim International Long Acting Beta Agonist Product Offered
  11.4.3 Boehringer Ingelheim International Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Boehringer Ingelheim International Main Business Overview
  11.4.5 Boehringer Ingelheim International Latest Developments
11.5 Mylan
  11.5.1 Mylan Company Information
  11.5.2 Mylan Long Acting Beta Agonist Product Offered
  11.5.3 Mylan Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Mylan Main Business Overview
  11.5.5 Mylan Latest Developments
11.6 Teva
  11.6.1 Teva Company Information
  11.6.2 Teva Long Acting Beta Agonist Product Offered
  11.6.3 Teva Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Teva Main Business Overview
  11.6.5 Teva Latest Developments
11.7 Merck
  11.7.1 Merck Company Information
  11.7.2 Merck Long Acting Beta Agonist Product Offered
  11.7.3 Merck Long Acting Beta Agonist Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Merck Main Business Overview
  11.7.5 Merck Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Long Acting Beta Agonist Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Long Acting Beta Agonist Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Liquid
Table 4. Major Players ofTablet
Table 5. Long Acting Beta Agonist Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Long Acting Beta Agonist Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
Table 8. Long Acting Beta Agonist Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Long Acting Beta Agonist Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)
Table 11. Global Long Acting Beta Agonist Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Long Acting Beta Agonist Revenue Market Share by Player (2020-2025)
Table 13. Long Acting Beta Agonist Key Players Head office and Products Offered
Table 14. Long Acting Beta Agonist Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Long Acting Beta Agonist Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Long Acting Beta Agonist Market Size Market Share by Region (2020-2025)
Table 19. Global Long Acting Beta Agonist Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Long Acting Beta Agonist Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Long Acting Beta Agonist Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Long Acting Beta Agonist Market Size Market Share by Country (2020-2025)
Table 23. Americas Long Acting Beta Agonist Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
Table 25. Americas Long Acting Beta Agonist Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)
Table 27. APAC Long Acting Beta Agonist Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Long Acting Beta Agonist Market Size Market Share by Region (2020-2025)
Table 29. APAC Long Acting Beta Agonist Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Long Acting Beta Agonist Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Long Acting Beta Agonist Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Long Acting Beta Agonist Market Size Market Share by Country (2020-2025)
Table 33. Europe Long Acting Beta Agonist Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Long Acting Beta Agonist Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Long Acting Beta Agonist Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Long Acting Beta Agonist Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Long Acting Beta Agonist Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Long Acting Beta Agonist
Table 39. Key Market Challenges & Risks of Long Acting Beta Agonist
Table 40. Key Industry Trends of Long Acting Beta Agonist
Table 41. Global Long Acting Beta Agonist Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Long Acting Beta Agonist Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Long Acting Beta Agonist Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Long Acting Beta Agonist Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Sumitomo Dainippon Pharma Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 46. Sumitomo Dainippon Pharma Long Acting Beta Agonist Product Offered
Table 47. Sumitomo Dainippon Pharma Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Sumitomo Dainippon Pharma Main Business
Table 49. Sumitomo Dainippon Pharma Latest Developments
Table 50. AstraZeneca Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 51. AstraZeneca Long Acting Beta Agonist Product Offered
Table 52. AstraZeneca Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. AstraZeneca Main Business
Table 54. AstraZeneca Latest Developments
Table 55. GlaxoSmithKline Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 56. GlaxoSmithKline Long Acting Beta Agonist Product Offered
Table 57. GlaxoSmithKline Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. GlaxoSmithKline Main Business
Table 59. GlaxoSmithKline Latest Developments
Table 60. Boehringer Ingelheim International Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 61. Boehringer Ingelheim International Long Acting Beta Agonist Product Offered
Table 62. Boehringer Ingelheim International Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Boehringer Ingelheim International Main Business
Table 64. Boehringer Ingelheim International Latest Developments
Table 65. Mylan Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 66. Mylan Long Acting Beta Agonist Product Offered
Table 67. Mylan Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Mylan Main Business
Table 69. Mylan Latest Developments
Table 70. Teva Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 71. Teva Long Acting Beta Agonist Product Offered
Table 72. Teva Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Teva Main Business
Table 74. Teva Latest Developments
Table 75. Merck Details, Company Type, Long Acting Beta Agonist Area Served and Its Competitors
Table 76. Merck Long Acting Beta Agonist Product Offered
Table 77. Merck Long Acting Beta Agonist Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Merck Main Business
Table 79. Merck Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Long Acting Beta Agonist Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Long Acting Beta Agonist Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Long Acting Beta Agonist Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Long Acting Beta Agonist Sales Market Share by Country/Region (2024)
Figure 8. Long Acting Beta Agonist Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Long Acting Beta Agonist Market Size Market Share by Type in 2024
Figure 10. Long Acting Beta Agonist in Hospitals
Figure 11. Global Long Acting Beta Agonist Market: Hospitals (2020-2025) & ($ millions)
Figure 12. Long Acting Beta Agonist in Clinics
Figure 13. Global Long Acting Beta Agonist Market: Clinics (2020-2025) & ($ millions)
Figure 14. Long Acting Beta Agonist in Ambulatory Surgical Center
Figure 15. Global Long Acting Beta Agonist Market: Ambulatory Surgical Center (2020-2025) & ($ millions)
Figure 16. Long Acting Beta Agonist in Others
Figure 17. Global Long Acting Beta Agonist Market: Others (2020-2025) & ($ millions)
Figure 18. Global Long Acting Beta Agonist Market Size Market Share by Application in 2024
Figure 19. Global Long Acting Beta Agonist Revenue Market Share by Player in 2024
Figure 20. Global Long Acting Beta Agonist Market Size Market Share by Region (2020-2025)
Figure 21. Americas Long Acting Beta Agonist Market Size 2020-2025 ($ millions)
Figure 22. APAC Long Acting Beta Agonist Market Size 2020-2025 ($ millions)
Figure 23. Europe Long Acting Beta Agonist Market Size 2020-2025 ($ millions)
Figure 24. Middle East & Africa Long Acting Beta Agonist Market Size 2020-2025 ($ millions)
Figure 25. Americas Long Acting Beta Agonist Value Market Share by Country in 2024
Figure 26. United States Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 27. Canada Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 28. Mexico Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 29. Brazil Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 30. APAC Long Acting Beta Agonist Market Size Market Share by Region in 2024
Figure 31. APAC Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
Figure 32. APAC Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)
Figure 33. China Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 34. Japan Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 35. South Korea Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 36. Southeast Asia Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 37. India Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 38. Australia Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 39. Europe Long Acting Beta Agonist Market Size Market Share by Country in 2024
Figure 40. Europe Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
Figure 41. Europe Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)
Figure 42. Germany Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 43. France Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 44. UK Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 45. Italy Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 46. Russia Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 47. Middle East & Africa Long Acting Beta Agonist Market Size Market Share by Region (2020-2025)
Figure 48. Middle East & Africa Long Acting Beta Agonist Market Size Market Share by Type (2020-2025)
Figure 49. Middle East & Africa Long Acting Beta Agonist Market Size Market Share by Application (2020-2025)
Figure 50. Egypt Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 51. South Africa Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 52. Israel Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 53. Turkey Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 54. GCC Countries Long Acting Beta Agonist Market Size Growth 2020-2025 ($ millions)
Figure 55. Americas Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 56. APAC Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 57. Europe Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 58. Middle East & Africa Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 59. United States Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 60. Canada Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 61. Mexico Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 62. Brazil Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 63. China Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 64. Japan Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 65. Korea Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 66. Southeast Asia Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 67. India Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 68. Australia Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 69. Germany Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 70. France Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 71. UK Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 72. Italy Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 73. Russia Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 74. Egypt Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 75. South Africa Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 76. Israel Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 77. Turkey Long Acting Beta Agonist Market Size 2026-2031 ($ millions)
Figure 78. Global Long Acting Beta Agonist Market Size Market Share Forecast by Type (2026-2031)
Figure 79. Global Long Acting Beta Agonist Market Size Market Share Forecast by Application (2026-2031)
Figure 80. GCC Countries Long Acting Beta Agonist Market Size 2026-2031 ($ millions)